Covered are new reimbursement proposals, approvable drugs, new technology items, and other issues
ACE Inhibitors Show Lower Risk of MACE for Older Patients With Type 2 Diabetes
Angiotensin-converting enzyme inhibitors have been known to be more effective in decreasing the incidence of major adverse cardiac events for patients with diabetes.
Demystifying PBMs, Their Role in the Drug Supply Chain
President of 3 Axis Advisors and CEO of 46brooklyn Research joins Drug Topics to discuss nuances surrounding pharmacy benefit managers and the way they are perceived in the public eye.
Calories to Satiation Predicts Patients Likely to Experience Adverse Events From GLP-1s
Patients often have anxiety about potential adverse effects, and experiencing adverse effects can affect patient adherence.
Scripted for Her: Helping Patients Choose Contraceptive Methods
In this episode of the podcast, Natalie DiPietro Mager, PharmD, PhD, sits down with Jasmine Cutler, PharmD, CPh.
FDA Grants Ustekinumab-Aekn Interchangeability Designation for Stelara
Selarsdi is interchangeable for all indications of ustekinumab, including treatment of psoriatic arthritis, plaque psoriasis, Crohn disease, and ulcerative colitis.
Demystify Your Purchasing Plan
